Plus   Neg

Stock Alert: Aprea Tanks 80% After Blood Cancer Drug Trial Fails To Meet Main Goal

Shares of Aprea Therapeutics Inc. (APRE) are currently plunging nearly 80% after the biopharmaceutical company focused on cancer therapy said a late-stage trial of blood cancer drug failed to meet primary endpoint.

APRE is currently trading at $5.69, down $19.40 or 77.32% on Nasdaq.

Aprea Therapeutics announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine versus AZA alone in TP53 mutant myelodysplastic syndromes. The trial did not meet the primary endpoint of complete remission rate.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer has uncovered the counterfeit versions of its Covid-19 vaccine in Mexico and Poland, according to a Wall Street Journal report. The vaccine was developed in partnership with Germany's BioNTech SE. Though there have been several reports of counterfeit versions of the Covid-19 vaccine, this seems to be the first confirmed instance. American Airlines is planning to resume hiring pilots this year to meet a rebound in travel demand in the summer season, reports said citing a company memo. The airline is expected to add 300 pilots by the end of the year and double that in 2022. Verizon Communications Inc. (VZ) reported a profit for the first-quarter that increased 25.4 percent from last year, reflecting growth in wireless service revenue, wireless equipment revenue and total Fios Internet net additions. Quarterly operating revenues rose 4.0 percent from the prior year.
Follow RTT